We compared the outcomes of unrelated donor (URD, n= 358) with human leukocyte
antigen (HLA)–matched sibling donor (MSD, n= 226) transplantations in patients with acute …

We compared the treatment-related mortality, relapse rate, disease-free survival (DFS), and
overall survival (OS) by cytogenetic risk group of 261 patients with acute myeloid leukemia …

Approximately one-third of patients with an indication for hematopoietic cell transplantation
(HCT) have an HLA-matched related donor (MRD) available to them. For the remaining …

Background Optimal post-remission strategy for patients with acute myeloid leukemia (AML)
is matter of intense debate. Recent reports have shown stronger anti-leukemic activity but …

Approximately 13% of patients lacking an HLA-identical sibling have a one-antigen–
mismatched related donor (MMRD). Historically, outcomes from the use of a one-antigen …

Most acute myeloid leukaemia (AML) patients lack human leucocyte antigen‐identical
sibling donors for transplantation. Autotransplants and unrelated donor (URD) transplants …

The effects of HLA-identical sibling donor (ISD) hematopoietic stem cell transplantation
(HSCT) on adults with intermediate-or high-risk acute myeloid leukemia (AML) in the first …

Refractory or relapsed acute myeloid leukemia (R/R-AML) has poor prognosis. Allogeneic
hematopoietic stem-cell transplantation (HSCT) may provide cure in this scenario. We …

This study aimed to investigate graft-versus-leukemia (GVL) of haploidentical donor (HID)
compared with HLA-matched sibling donor (MSD) for high-risk acute myeloid leukemia (H …

The optimal post-remission treatment for acute myeloid leukemia in first complete remission
remains uncertain. Previous comparisons of autologous versus allogeneic hematopoietic …